Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...
Posted by Michael Wonder on 09 Jan 2020
New treatment approved in Canada for most common type of leukaemia
8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 08 Jan 2020
AbbVie receives Health Canada approval of Rinvoq (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis
7 January 2020 - Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis program, one ...
Posted by Michael Wonder on 02 Jan 2020
HLS Therapeutics announces Health Canada approval for Vascepa to reduce the risk of cardiovascular events
1 January 2020 - Health Canada approval follows priority review for Vascepa. ...
Posted by Michael Wonder on 17 Dec 2019
Health Canada approves new indication for Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 December 2019 - Janssen announced today that Health Canada, following a priority review, has approved Erleada (apalutamide) for the ...
Posted by Michael Wonder on 12 Dec 2019
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has ...
Posted by Michael Wonder on 07 Dec 2019
International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer
6 December 2019 - Health Canada also provides an update on approvals of new drugs and medical devices for Canadians. ...
Posted by Michael Wonder on 28 Nov 2019
Health Canada approves Ofev (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
27 November 2019 - Boehringer Ingelheim announced today that Health Canada has approved Ofev (nintedanib) as the first and only treatment ...
Posted by Michael Wonder on 26 Nov 2019
Seattle Genetics announces Health Canada approval of Adcetris (brentuximab vedotin) in combination with chemotherapy in frontline CD30-expressing peripheral T-cell lymphoma
25 November 2019 - Approval of supplemental new drug aubmission for Adcetris in combination with CHP chemotherapy in frontline CD30-expressing peripheral ...
Posted by Michael Wonder on 21 Nov 2019
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukaemia
21 November 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration and Health Canada, ...
Posted by Michael Wonder on 13 Nov 2019
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of patients with previously treated advanced hepatocellular carcinoma
12 November 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 ...
Posted by Michael Wonder on 09 Nov 2019
Xeomin Cosmetic licensed for additional indications In Canada
7 November 2019 - Merz Pharma has announced that Health Canada has provided marketing authorization for additional indications for Xeomin ...
Posted by Michael Wonder on 09 Nov 2019
Janssen announces Health Canada approval of Imbruvica (ibrutinib) in combination with obinutuzumab for treatment naïve patients with chronic lymphocytic leukaemia
8 November 2019 - Patients experienced a 77% reduction in risk of disease progression or death compared to chlorambucil plus obinutuzumab. ...
Posted by Michael Wonder on 07 Nov 2019
Endoceutics receives Health Canada approval for Intrarosa
6 November 2019 - The first innovative drug for the treatment of vulvovaginal atrophy with prasterone. ...
Posted by Michael Wonder on 31 Oct 2019
Janssen announces Health Canada approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are transplant ineligible
30 October 2019 - This Darzalex combination regimen reduced the risk of disease progression or death by 44% in newly ...